Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observation

Journal of Infectious Diseases

Volumn 208, Issue 9, 2013, Pages 1391-1396

  Szarewski, Anne ^a   Skinner, S Rachel ^b,c   Garland, Suzanne M ^d,e,f,g   Romanowski, Barbara ^h   Schwarz, Tino F ⁱ   Apter, Dan ^j   Chow, Song Nan ^k   Paavonen, Jorma ^l   Del Rosario Raymundo, M Rowena ^m   Teixeira, Julio C ⁿ   De Carvalho, Newton S ^o   Castro Sanchez, Maria ^p   Castellsagué, Xavier ^q   Poppe, Willy A J ^r   De Sutter, Philippe ^s   Huh, Warner ^t   Chatterjee, Archana ^u   Tjalma, Wiebren A ^v   Ackerman, Ronald T ^w   Martens, Mark ^x   Papp, Kim A ^y   Bajo Arenas, Jose ^z   Harper, Diane M ^aa   Torné, Aureli ^ab   David, Marie Pierre ^ac   Struyf, Frank ^ac   Lehtinen, Matti ^ad   Dubin, Gary ^ae   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ Stiftung Juliusspital   (Germany)

^j Infertility Clin Fam Fed Finland   (Finland)

^k NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^l UNIVERSITY OF HELSINKI   (Finland)

^m San Pablo Colleges Medical Center   (Philippines)

ⁿ UNIVERSITY OF CAMPINAS   (Brazil)

^o FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^p HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^q CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^r UNIVERSITY OF LEUVEN   (Belgium)

^s UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^t University of Alabama   (United States)

^u CREIGHTON UNIVERSITY   (United States)

^v ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^w Comprehensive Clinical Trials ^*  (United States)

^x JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^y PROBITY MEDICAL RESEARCH   (Canada)

^z HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^aa DARTMOUTH MEDICAL SCHOOL   (United States)

^ab UNIVERSITY OF BARCELONA   (Spain)

^ac GSK   (Belgium)

^ad TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^ae GLAXOSMITHKLINE   (United States)

more..

Author keywords

genital warts; HPV; HPV vaccine; human papillomavirus

Indexed keywords

ALUMINUM HYDROXIDE; ASO4 MIXTURE; IMMUNOLOGICAL ADJUVANT; LIPID A; WART VIRUS VACCINE;

ANALOGS AND DERIVATIVES; CONDYLOMATA ACUMINATA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; INCIDENCE; INCIDENTAL FINDING; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; CLINICAL TRIALS, PHASE III AS TOPIC; CONDYLOMATA ACUMINATA; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; INCIDENCE; INCIDENTAL FINDINGS; LIPID A; MULTICENTER STUDIES AS TOPIC; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VACCINATION;

EID: 84885393164     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit360     Document Type: Article

References (24)

1. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-Adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99
2. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10
3. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1157-64
4. Petäjä T, Keränen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine in healthy boys aged 10-18 years. J. Adolesc Health 2009; 44:33-40
5. Health Protection Agency Report Vol 5, No. 17; 28.04.11. http://www. hpa.org.uk/hpr/archives/2011/hpr1711.pdf. Accessed 15 July 12
6. Lanitis T, Carroll S, O'Mahony C, et al. The cost of managing genital warts in the UK. International Journal of STD & AIDS 2012; 23:189-94
7. Pirotta M, Ung L, Stein A, et al. The psychosocial burden of HPV-related disease and screening interventions. Sex Transm Infect. 2009; 85:508-13
8. Aubin F, Pretet JL, Jaquard AC, et al.; EDiTH Study Group. Human papillomavirus genotype distribution in external acuminatacondylomata. A large French national study (EDiTH IV). Clin Infect Dis 2008; 47:610-15
9. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: Analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11,16, and 18) vaccine. J Infect Dis 2009; 199:805-14
10. Hepburn HM, Schwarz TF, Perlitz H, Pacher SK, Schädlich L, Kaufmann AM. Long term ex vivo monitoring of memory CD4 T helper cell responses in women immunized with Gardasil® or Cervarix®. Presented at EUROGIN, Lisbon 2011. In: Abstract SS 19-6
11. Kube T, Rosenthal HE, Feger T, Pollok K, Schneider A, Kaufmann AM. CD4 T cell clones cross-react with homologous HPV L1-Derived peptides. In: Presented at 27th IPV Conference, Berlin, 17-22 September 2011 Abstract O-25.05
12. Department of Health Annual HPV vaccine coverage in England in 2010/11, published March 2012. https://www.wp.dh.gov.uk/immuni sation/files/2012/04/ 120319-HPV-UptakeReport2010-11-revised-acc. pdf. Accessed 15 July 12
13. Health Protection Report 31.05.12, Volume 6, No. 22. Sexually transmitted infection in England, 2011. http://www.hpa.org.uk/hpr/infec tions/hiv-sti.htm. Accessed 15 July 12
14. Howell-Jones R, Soldan K, Wetten S, et al. Decline in genital warts in young women in England associated with HPV 16/ 18 vaccination: An ecological study. J Infect Dis 2013. In Press
15. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14
16. van Doorn L-J, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44:3292-8
17. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337:76-84
18. Pacher SK, Rosenthal HE, Perlitz H, et al. Direct longitudinal comparison over 12 month of T cell responses to prophylactic HPV vaccines. In: Presented at IPV conference, Beijing, 2010. Oral communication: Basic Science 5
19. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/ vaccine: Follow-Up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7: 1343-58
20. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359-73
21. Hepburn HM, Rosenthal HE, Seipel M, et al. Ex vivo monitoring. Ex vivo monitoring of cellular memory responses in young women immunized with either Gardasil® or Cervarix® four years prior to enrolment. In: International Papillomavirus Congress, Malmö, 2009, Poster P-13-13
22. Lehtinen M, Paavonen J. Sound efficacy of prophylactic HPV vaccination. Basics and implications. Oncoimmunology 2012; 1:995-6
23. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010; 118(1 Suppl):12-7
24. Salisbury D. Male vaccination against human papillomavirus. Lancet Infect Dis 2012; 12:582-3